India's first indigenous Covid-19 vaccine Covaxin, developed by Bharat Biotech in association with Indian Council of Medical research, was found to be "well tolerated in all dose groups with no vaccine-related serious adverse events," in the interim findings of phase 1 trial of Covaxin, confirmed the vaccine manufacturer.Bharat Biotech in a statement also said that after first vaccination, "local and systemic adverse events were predominantly mild/moderate in severity & resolved rapidly, without prescribed medication."The trials were conducted on 375 volunteers, Bharat Biotech said in a research paper. "All three vaccine formulations resulted in robust immune responses comparable to a panel of convalescent serum," the company stated. It also said that most common adverse event was pain at the injection site which resolved spontaneously.
Currently, the Hyderabad-based Bharat Biotech is in phase three of clinical trial with over 22,000 volunteers at 18 sites across the country. It has also applied for emergency use authorisation.Besides, Covaxin, four other vaccines are under different phases of clinical trial in India with the Serum Institute of India conducting phase-three trial of the Oxford-Astrazeneca COVID-19 vaccine while the indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country. The World Health Organization said that a team of international experts would travel to China next month to help investigate the animal origins of Covid-19. India’s coronavirus tally rose to 99,32,547 on Wednesday as it registered 26,382 new cases in 24 hours. The country’s toll rose by 387 to 1,44,096. India’s active cases stood at 3,32,002, while the recoveries reached 94,56,449. Wednesday’s new cases are 19.5% higher than the previous day.